HC Wainwright & Co. Maintains Buy on Kiora Pharmaceuticals, Adjusts Price Target To $10 (1-9 Reverse Stock Split)
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on Kiora Pharmaceuticals (NASDAQ:KPRX) and adjusted the price target to $10 from $2 following a 1-9 reverse stock split.
July 23, 2024 | 5:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has maintained a Buy rating on Kiora Pharmaceuticals and adjusted the price target to $10 from $2 following a 1-9 reverse stock split.
The maintenance of a Buy rating and the significant adjustment in the price target to $10 from $2 following a reverse stock split is a positive signal for investors. This suggests confidence in the company's future performance and could lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100